Fig 1: Gilteritinib and Venetoclax combined treatment releases BIM from the pro-survival proteins BCL-2 and MCL-1 to trigger apoptosis/cell death. a Co-immunoprecipitation followed by western blot analysis for BIM binding proteins after 24 h of treatment with Gilteritinib and/or Venetoclax. b Western blot analysis for p-GSK3 and GSK3 expression in Molm14 cells treated for 1 h and 24 h. c Co-immunoprecipitation analysis for BID, BIK, and PUMA binding proteins after 24 h treatment. Input levels of the immunoprecipitated proteins are shown below. d Western blot analysis for BIM protein in negative control (si-NC) and si-BIM group. e 48 h MTT and f 48 h apoptosis analysis for Molm14-si-NC and Molm14-si-BIM cells treated with Gilteritinib and Venetoclax at the indicated concentrations